Thomas Laur, DNAnexus | theCUBE + NYSE Wired: MedTech Unplugged

In this episode of theCUBE + NYSE Wired: MedTech Unplugged, Thomas Laur, CEO of DNAnexus, discusses the evolution of healthcare data management, specifically the integration of multiomics into modern care. He explains that while there is great potential in precision medicine, the real challenge lies in the effective execution and organization of omics-enabled data. DNAnexus offers a cloud platform that enables organizations to manage vast amounts of biological data, helping to normalize and analyze it securely. Laur emphasizes the importance of infrastructure that meets governance and quality requirements, facilitating the shift from trial-and-error approaches to more predictive, personalized therapies, particularly in oncology. The conversation highlights how AI's impact in healthcare is contingent on better data organization and collaborative frameworks.

• The significance of "omics" as core data in healthcare.
• DNAnexus's role in providing a compliant cloud platform for multiomics data.
• The transition from traditional drug discovery to precision medicine.
• Challenges of organizing dense omics data within current infrastructures.
• The need for predictive models in drug calibration as opposed to trial and error.
• Collaboration between various sectors, including pharma and diagnostics.
• The "N plus one" revolution in personalized medicine emphasizing individualized treatment.
• Future implications of AI and omics data in advancing healthcare beyond traditional boundaries.